Schroder UK Public Private Trust plc
Transaction Overview
In January 2021, Rosetta Capital completed a secondary transaction to acquire a portfolio of seven life sciences assets from Schroder UK Public Private Trust plc, an large UK-based investment trust, for a total acquisition price of £49.0 million with an agreement to provide follow-on capital to support those companies through value creation.
The sale portfolio consisted of holdings in Carrick Therapeutics, Mission Therapeutics, PsiOxus Therapeutics, ReNeuron and Mereo BioPharma. Portfolio company Inivata was subsequently sold to NeoGenomics and Immunocore successfully listed on Nasdaq.
Carrick Therapeutics
Pharmaceutical
Mission Therapeutics
Biotech
Immunocore
Biotech
Mereo Biosciences
Biotech
Supporting portfolio companies for the next growth phase
Rosetta Capital is committed to supporting the portfolio companies acquired in the transaction through the growth phase and has made several follow-on investments.
Rosetta partners Jonathan Hepple and Ken MacLeod have joined the boards of acquired portfolio companies and are actively involved in strategic decision making.
The basket transaction being announced today is a further important milestone for the Company and delivers against that communicated goal. We are delighted to welcome Rosetta Capital as co-shareholders in ReNeuron, Immunocore and Inivata and we welcome their expertise and experience. We are looking forward to continuing to work with the management teams of the Company’s holdings in delivering sustainable value and positive long-term shareholder returns.”
Tim Creed and Ben Wicks
Portfolio Managers at Schroder UK Public Private Trust plc
